{
}
Sanofi has partnered with U.K.-based Healx to leverage AI in identifying new rare disease indications for a discontinued drug asset. Healx will utilize its AI-driven platform, Healnet, to analyze data provided by Sanofi, aiming to support the compound's future development. This collaboration underscores both companies' commitment to innovative therapies for patients with limited treatment options.
Michael Palladinetti
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Sanofi and Healx Collaborate to Explore New Treatments for Rare Diseases
03:24 14.11.2024
Trending
Subcategory
Industry Trends
Corporate News
Global Trade Developments
Supply Chain Management
Government Economic Policies
Startups & Entrepreneurship
Retail and Consumer Goods
Energy Sector Developments
Emerging Startups
Industry Mergers & Acquisitions
Tax Policy & Corporate Taxation
CEO Changes
Funding Rounds & Investments
Foreign Exchange Rates
Financial Scams and Security
Finance Mergers & Acquisitions
Market Analysis and Predictions
Central Bank Actions
Fintech Startups
Banking & Investment Regulations
Countries:
Companies:
Apple Inc.
Learning Resources Inc.
MGA Entertainment Inc.
State Street Global Advisors Luxembourg SICAV - SSGA EMU ESG Screened Equity Fund
European Union Bonds
SLB 4,6% 01JUN25
Equinor Ventures AS
Quanta Services, Inc.
Gold Circuit Electronics Ltd.
Unimicron Technology Corp.
Yatra Online, Inc.
Daiwa Institute OF Research Ltd.
Pegatron Corporation
KODEX India Tata Group
Wistron Corporation
Foxconn Technology Co., Ltd.
Volkswagen AG
XIAOMI-W
XPeng Inc.
Tesla, Inc.
Currencies:
United States Dollar
Chinese Yuan
Indian Rupee
United Arab Emirates Dirham
Vietnamese Đồng
New Taiwan Dollar
Japanese Yen
Euro
Australian Dollar
Thai Baht
Saudi Riyal
People: